Publication of first ever head-to-head comparison of gut microbiome changes associated with novel oral preclinical PolC (pol IIIC*) inhibitors to linezolid ...

Kiszala, the CEO and co-founder of intoDNA, to explore how a breakthrough in understanding DNA damage and repair could ...

A review of 86 cellular, animal and clinical studies reports multiple antitumor mechanisms for ginsenosides in liver-cancer ...

FDA approves Hibsago (bepirovirsen) with NrtI therapy for adult chronic hepatitis B without cirrhosis; phase 3 trials show up to 20% functional cure at 72 weeks.

People age and eventually die.This is such an obvious fact that we do not even question it. When told it is a "law of nature" ...

More than 41 million people are living with HIV worldwide, and approximately 570,000 died from AIDS-related illnesses in 2025 ...

A newly isolated lytic bacteriophage significantly reduced Vibrio parahaemolyticus on artificially contaminated fish muscle ...

Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with ...

A teeny-tiny archaea with one of the smallest genomes ever discovered is pushing the limits of what it means to be alive.

Living organisms have inherited the results of environmental adaptation to the next generation through DNA. Evolution is ...

GSK’s bepirovirsen (Hibsago) has secured FDA approval for the treatment of chronic hepatitis B virus (HBV), when used with existing antiviral therapy in adults without cirrhosis. “This is the start of ...

The total number of BKVAN cases across the 7MM is expected to increase from approximately 4,000 cases in 2025, reflecting the growing kidney transplant population, continued exposure to ...